No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CDMO240621C7500
- 0.55
- -0.35-38.89%
15min DelayClose Jun 14 15:55 ET
0.55High0.09Low
0.09Open0.90Pre Close3 Volume62 Open Interest7.50Strike Price119.00Turnover208.24%IV13.62%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type0.4626Delta0.2207Gamma12.88Leverage Ratio-0.0694Theta0.0004Rho5.96Eff Leverage0.0034Vega
Intraday
- 5D
- 1D
News
Insider Stock Buying Reaches US$527.5k On Avid Bioservices
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Avid Bioservices, Inc.'s (NASDAQ:CDMO) instance, it's good news for sha
Those Who Invested in Avid Bioservices (NASDAQ:CDMO) Five Years Ago Are up 104%
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersAutonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNC
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum analyst Matt Hewitt maintains $Avid Bioservices(CDMO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.9% and a total average return of -3.8% over th
Vetter Announces Plans to Expand Its Capacity in the U.S. and Germany
Leading globally operating CDMO outlines location and design of new manufacturing sites to meet increasing customer demands Vetter Advisory Board decides on strategic path forward for further independ
BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform From CelluTx
ADELAIDE, South Australia, June 3, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to u
Comments
Investors' belief in Societal CDMO's lackluster revenue performance not improving may be causing its low P/S ratio. The company's inferior revenue outlook compared to the industry average contributes to this. A significant change in fortune is needed to justify a higher P/S.
Societal CDMO, Inc.'s (NASDAQ:SCTL) Shares Bounce 29% But Its Business Still Trails The Industry 1
The company's high debt and lack of profitability strain its balance sheet. Negative free cash flow adds risk, but its US$417.4m market cap could potentially allow capital raising to strengthen the balance sheet.
Investors' belief in Avid Bioservices' stagnant revenue performance and future growth lagging behind the industry has led to its low P/S. The underwhelming revenue outlook and shareholders' pessimism impact the P/S negatively.
Despite good revenue growth, the market expected more, as seen in the share price drop. This could hint at delayed revenue growth. The recent sell-off might be an investment chance considering the signs of a continued growth trend.
$FedEx(FDX.US$ $La-Z-Boy(LZB.US$ $Dynagas LNG Partners LP(DLNG.US$ $Winnebago Industries(WGO.US$ $KB Home(KBH.US$ $Algoma Steel(ASTL.US$ $Steelcase(SCS.US$ $Avid Bioservices(CDMO.US$ $Accenture(ACN.US$ $Darden Restaurants(DRI.US$ $FactSet Research Systems(FDS.US$ $Globex Mining Enterprises Inc(GMX.CA$ $GMS Inc(GMS.US$ $Commercial Metals(CMC.US$ $Methode Electronics(MEI.US$ $CAPSTONE COMPANIES INC(CAPC.US$ $CarMax(KMX.US$ $Apogee Enterprises(APOG.US$
...
...
2
Read more